CLINICAL_TRIALS
trial_result
· 2007-07-25
Clinical Trial Update: Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia [Phase 2]
Summary
Phase 2 study evaluating the safety of subcutaneous alemtuzumab in patients with B-cell chronic lymphocytic leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karolinska University Hospital | Conditions: B-CLL | Phase 2 | Status: COMPLETED